This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Groups

Education and Academic Career

PD Dr. med. Juliane Walz née Stickel
 

Since 09/2020

Head of AG Immunotherapy Robert Bosch Cancer Centre, Stuttgart and Senior physician CCU Translational Immunology, University Hospital Tübingen

Since 07/2020  

Head of the “Wirkstoffpeptidlabor”, Department of Immunology, University of Tübingen

09/2019 - 08/2020

Senior physician CCU Translational Immunology/Department of Hematology and Oncology

04/2019 - 08/2019   

Research scholarship, National Institute of Health (NIH), lab of Prof. Tim Greten, Bethesda, USA

05/2018       

Habilitation (internal medicine) at the Medical Faculty, Eberhard Karls University Tübingen

05/2017 - 03/2019 

Specialist for internal medicine and hematology and oncology at the University Hospital Tübingen, Medical Department II

Since 01/2012 

Research group leader Department of Immunology, University Tübingen „Peptide-based immunotherapy“

04/2011   

Medical dissertation MD, summa cum laude

2011 - 2017 

Residency at the University Hospital Tübingen, Medical Department II

2004 - 2010

Medical school, Eberhard Karls University Tübingen

 Scholarships, Awards, Qualifications
 

2020

Poster Award of the University Tübingen, research colloquium

2018

Poster Award DGHO Wien

2017

Poster Award of the University Tübingen, research colloquium

2016

Young Investigator Award DGHO Leipzig

2015

Württembergischer Krebspreis, junior award

2015

Poster Award DGHO Basel

2014

Abstract Achievement Award American Society of Hematology

2013

Abstract Achievement Award American Society of Hematology

2012

Abstract Achievement Award American Society of Hematology

2011

Ludolf Krehl Award of the Süddeutschen Gesellschaft für Innere Medizin

2011

Dissertation award of the Eberhard Karls University Tübingen

 Patents
 

2020  

CoVac-1 peptide cocktail: PCT/EP 20 190 070.1

2020

SARS-CoV-2 CD8+ und CD4+ T cell epitopes: PCT/EP 20 169 047.6

2018

Peptides and combination thereof for use in the immunotherapy against cancers: PCT/EP2018/059109

2018

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers: PCT/EP2018/059114

2016

Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers: PCT/EP2016/064317

2014

Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)” Priority application: UK Nr. 1411037.3 und US 62/014,849

2014

Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) Priority application: UK Nr. 1408255.6 und US 61/990,980